Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double-blind, randomised study - Commentary

Tom Huizinga*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double-blind, randomised study - Commentary'. Together they form a unique fingerprint.